You are here: Industry Insights > Kidney Cancer

News List

Need for Speed: Kidney cancer patients waiting three times longer pharmatimes
February 08, 2022
Need for Speed: Kidney cancer patients waiting three times longer.
US clears Keytruda, Lenvima combo in first-line kidney cancer firstwordpharma
August 12, 2021
The FDA announced Wednesday that it approved the combination of Merck & Co.'s anti-PD-1 therapy Keytruda (pembrolizumab) and Eisai's oral multi-kinase inhibitor Lenvima (lenvatinib) as a first-line treatment for adults with advanced renal cell carcinoma.
Survey finds kidney cancer patients face anxiety over delayed scan results pharmatimes
July 12, 2021
A new survey from Kidney Cancer UK has found that kidney cancer patients under surveillance following surgery are facing anxiety through long waits for their scan results.
Two new developments in kidney cancer treatments europeanpharmaceuticalreview
February 19, 2021
Studies suggest there are better treatment options than sunitinib for kidney cancers; cabozantinib in metastatic papillary kidney cancer and lenvatinib/pembrolizumab for renal cell carcinoma.
Glenmark launches SUTIB (Sunitinib) capsules in India to treat kidney cancer expresspharma
February 18, 2021
The company informs that the drug is priced 96 per cent lower than the innovator brand and reduces the risk of kidney cancer progression by 58 per cent.
Adagene Achieves CAR-T Collaboration Milestone contractpharma
January 13, 2021
Yields potential first-ever antibodies targeting human endogenous retrovirus associated with kidney cancer.
BDR Pharma launches generic version of Lenvatinib in India expresspharma
October 22, 2020
It is indicated for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer.
NICE recommends avelumab and axitinib to treat renal cell carcinoma europeanpharmaceuticalreview
August 03, 2020
Bavencio (avelumab) and Inlyta (axitinib) are recommended by NICE for the treatment of advanced renal cell carcinoma, available on the Cancer Drugs Fund.
NICE backs Bavencio combo for kidney cancer pharmatimes
July 31, 2020
The National Institute for Health and Care Excellence (NICE) has recommended NHS use of Merck and Pfizer's immunotherapy Bavencio (avelumab) in combination with axitinib as a first-line treatment for kidney cancer.
Bristol Myers says Opdivo performs well in kidney, lung cancer trials expresspharma
April 22, 2020
Opdivo is one of Bristol’s top-selling drugs, but sales of the drug have slowed in recent years as it has been eclipsed by Merck & Co’s rival drug Keytruda.

Previous page 1 2 3 4 Next page